Becton Dickinson (BDX) vs DexCom (DXCM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DexCom (DXCM) has outperformed Becton Dickinson (BDX) over the past year, gaining 27.7% versus a gain of 19.0%. Over five years, BDX leads with a -2.6% price change compared with -38.1% for DXCM. Becton Dickinson is the larger company by market cap ($49.07 billion vs $31.81 billion), about 1.5 times the size, while DexCom is growing revenue faster (+15.6% vs +8.2%).
On valuation, Becton Dickinson trades at a lower forward P/E (13.5x vs 27.0x for DexCom). Becton Dickinson pays a dividend yielding 2.33%, while DexCom does not currently pay one. DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 7.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDX | DXCM |
|---|---|---|
| Share price | $180.16 | $84.30 |
| Market cap | $49.07B | $31.81B |
| 1-day change | -0.08% | +1.09% |
| YTD return | +18.08% | +27.02% |
| 1-year return | +19.03% | +27.67% |
| 5-year return | -2.60% | -38.07% |
| P/E ratio (TTM) | 41.90 | 33.45 |
| Forward P/E | 13.54 | 26.96 |
| EPS (TTM) | $4.30 | $2.52 |
| Dividend yield | 2.33% | 0.00% |
| Annual dividend | $4.19 | $0.00 |
| Revenue (latest FY) | $21.84B | $4.66B |
| Revenue growth (YoY) | +8.24% | +15.60% |
| Net income (latest FY) | $1.68B | $836.30M |
| Gross margin | 45.44% | 60.10% |
| Operating margin | 11.81% | 19.56% |
| Net margin | 7.68% | 17.94% |
| 52-week high | $193.07 | $92.59 |
| 52-week low | $127.59 | $54.11 |
| Distance from 52-week high | -6.69% | -8.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +7.73% | +14.15% |
| Average volume | 1.78M | 4.47M |
| Shares outstanding | 272.39M | 377.36M |
| Employees | 72,000 | 11,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Becton Dickinson trades at a higher earnings multiple (41.9x vs 33.5x trailing P/E).
- Becton Dickinson offers a meaningfully higher dividend yield (2.33% vs 0.00%).
- DexCom is more profitable, keeping 17.9 cents of every revenue dollar as net income versus 7.7 cents for Becton Dickinson.
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +8.24%).
About Becton Dickinson
BDX stock →Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Health Care · Medical/Dental Instruments · 72,000 employees
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
BDX vs DXCM FAQ
Which is bigger, Becton Dickinson or DexCom?
Becton Dickinson (BDX) is larger, with a market capitalization of $49.07B compared with $31.81B for DexCom (DXCM).
Which stock has performed better over the past year, BDX or DXCM?
DXCM returned +27.67% over the past 12 months, compared with +19.03% for BDX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BDX or DXCM?
DXCM has the lower trailing P/E at 33.5, versus 41.9 for BDX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Becton Dickinson or DexCom?
Becton Dickinson pays a dividend yielding 2.33%, while DexCom does not currently pay a regular dividend.
Are Becton Dickinson and DexCom in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.